RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > In Focus: GxPs

In Focus: GxPs

Posted 01 July 2008

Regulatory personnel need to know what constitute "good practices" and, moreover, what constitute "current" good practices. As we deal with regulatory agencies such as FDA, we meet and agree upon a course of action. This course may include manufacturing considerations or a clinical development plan. When we complete the work and submit it to FDA, the agency often adds to the activity or disagrees with what has been done. When asked why it wants to change what had been agreed, FDA says things have "evolved." This non-Darwinian evolution is the state of the art at a given time, or "current" good practices.


© 2022 Regulatory Affairs Professionals Society.